CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 29 enrolled
Drug / intervention
alendronate with cholecalciferol +2 moredrug
Likely dose
alendronate with cholecalciferol 70mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00421343
NCT00421343Phase 3Completed
CompareCT.gov

Secondary Prevention of Osteoporosis: A Window of Opportunity in the Acute Rehabilitation Setting

Hebrew SeniorLife·interventional·Posted Jan 12, 2007·Updated Feb 5, 2020

In Brief

A Phase 3 clinical trial evaluating alendronate with cholecalciferol, calcium carbonate with cholecalciferol, and 1 other intervention for Osteoporosis. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Merck Sharp & Dohme LLC, GlaxoSmithKline

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 12, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.5 years ago

Interventions

alendronate with cholecalciferoldrug

alendronate 70mg /cholecalciferol 2800IU orally once weekly

calcium carbonate with cholecalciferoldrug

calcium carbonate 500mg /cholecalciferol 200IU orally twice daily

Falls prevention measuresbehavioral

personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications